After Pfizer CEO Albert Bourla said a fourth COVID shot may be needed sooner than expected amid the rise of the Omicron variant, Twitter users were quick to criticize the drugmaker head. Some took to the social media platform on Thursday to claim the additional vaccine would just be a moneymaker for the company.

Bourla made the comments on CNBC’s “Squawk Box” on Wednesday after preliminary data showed a third dose of the shot developed by the company and BioNTech was more effective at fighting off the Omicron variant compared to the initial two-dose vaccination series.

However, Bourla maintained real-world data would be more accurate as the preliminary data was a synthetic, lab-created copy of the variant.

“When we see real-world data, will determine if the Omicron is well covered by the third dose and for how long,” Bourla told “Squawk Box.” “And the second point, I think we will need a fourth dose.”

According to CNBC, Bourla had previously suggested that a fourth shot would be needed 12 months after the third dose of the COVID vaccine. He said: “With Omicron we need to wait and see because we have very little information. We may need it faster.”

But some on Twitter saw the comments from Bourla a little differently, accusing the drugmaker of using the Omicron variant as an opportunity to cash in on another inoculation.

One Twitter user criticized Bourla by writing a post that said, the “Pfizer CEO should just say 'ITS ALL ABOUT THE MONEY.'”

Another Twitter user slammed the CEO with a tongue-in-cheek post that suggested by Friday he will be suggesting “five doses best protects against covid.”

Still another Twitter poster chided the Pfizer head by posting, “Pfizer CEO right now: 'Get all the boosters. They’re important for me, I mean for you.'”

Another user on Twitter claimed that Bourla was suggesting a fourth COVID shot so he could get a “fourth yacht” sooner.

Others jumped on the yacht accusations, with a series of Twitter users accusing Bourla of shopping for a vessel.

Pfizer has said that it could reformulate its COVID vaccine to be effective against the Omicron variant, if required, as soon as early 2022.

Over 276.4 million doses of the Pfizer-BioNTech vaccine have been administered in the U.S., according to data from the Centers for Disease Control and Prevention. Over 26.6 million Pfizer booster shots have been given out to eligible Americans as well, the agency said.

Pfizer vaccine
The Pfizer vaccine is pictured. AFP / THOMAS KIENZLE